17Alpha-hydroxyprogesterone - CAS 68-96-2
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
17Alpha-hydroxyprogesterone
Catalog Number:
68-96-2
Synonyms:
Hydroxyprogesterone; (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one;
CAS Number:
68-96-2
Description:
17α-Hydroxy Progesterone, as a metabolite of Progesterone, is an endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones
Molecular Weight:
330.47
Molecular Formula:
C21H30O3
Quantity:
Grams-Kilos
Quality Standard:
Enterprise Standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC(=O)C1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)O
InChI:
1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1
InChIKey:
DBPWSSGDRRHUNT-CEGNMAFCSA-N
Targets:
Others
Chemical Structure
CAS 68-96-2 17Alpha-hydroxyprogesterone

Related Products


CAS 1143-38-0 Dithranol

Dithranol
(CAS: 1143-38-0)

Dithranol is a hydroxyanthrone, anthracene derivative, medicine applied to the skin of people with psoriasis.

CAS 50-81-7 Vitamin C

Vitamin C
(CAS: 50-81-7)

Ascorbic acid is a naturally occurring organic compound with antioxidant properties.

CAS 33171-05-0 Bisdemethoxycurcumin

Bisdemethoxycurcumin
(CAS: 33171-05-0)

Bisdemethoxycurcumin is one of the three major forms of curcuminoids found in the rhizomes of turmeric. Bisdemethoxycurcumin displays antioxidant, anti-inflamma...

GSK2256294A
(CAS: 1142090-23-0)

GSK2256294A, an effective inhibitor of human soluble epoxide hydrolase(sEH), was developed by GSK and still under Phase I trial in Chronic obstructive pulmonary...

CAS 109-57-9 Allylthiourea

Allylthiourea
(CAS: 109-57-9)

Allylthiourea is a metabolic inhibitor that selective inhibits ammonia oxidation.

CAS 1146-98-1 Bromindione

Bromindione
(CAS: 1146-98-1)

Bromindione, an inandione derivative, could be used as an orally bioavaliable anticoagulant.

CGP-75254A
(CAS: 199485-26-2)

CGP-75254A, a novel oral iron chelator, across Caco-2 cells in an attempt to model intestinal epithelial cell permeability in man. Studies predicted that absorp...

CAS 1492-02-0 Glybuzole

Glybuzole
(CAS: 1492-02-0)

Glybuzole, a benzenesulfonamide derivative, has been found to have antihyperglycemic through stimulating the release of insulin.

CAS 5578-73-4 Sanguinarine chloride hydrate

Sanguinarine chloride hydrate
(CAS: 5578-73-4)

Sanguinarine is a benzylisoquinoline alkaloid isolated from Papaveraceae with antimicrobial, anti-inflammatory, and anti-oxidant properties.

CAS 140678-14-4 Mangafodipir Trisodium

Mangafodipir Trisodium
(CAS: 140678-14-4)

The trisodium salt form of Mangafodipir that has been found to be a contrast agent through intravenously Mangafodipir Trisodium is a contrast agent delivered in...

Epelsiban besylate
(CAS: 1159097-48-9)

This active molecular, also known as GSK-557296B is a selective, sub-nanomolar (Ki=0.13 nM) oxytocin receptor antagonist with more than 30000-fold selectivity o...

ABT116
(CAS: 1008529-42-7)

ABT116 is an antagonist of transient receptor potential vanilloid type 1.

CAS 7432-28-2 Schisandrin

Schisandrin
(CAS: 7432-28-2)

Schisandrin has various therapeutic effects on a range of medical conditions such as anti-asthmatic, anti-cancer, and anti-inflammatory effects.

CAS 31112-62-6 Metrizamide

Metrizamide
(CAS: 31112-62-6)

Metrizamide is a X-ray contrast agent related to Metrizoic Acid, used as a diagnostic aid (radiopaque medium).

MK-B 251
(CAS: 40396-69-8)

MK-B 251 is a synthetic bio-active chemical.

Vadadustat
(CAS: 1000025-07-9)

Vadadustat is a potent Hypoxia-inducible factor-proline dioxygenase inhibitor, which leads to stabilization and increased levels of HIFα. It is used for the tre...

CAS 106791-40-6 Mivacurium

Mivacurium
(CAS: 106791-40-6)

Mivacurium is a bisbenzylisoquinolinium based and a short-duration non-depolarizing neuromuscular-blocking drug or skeletal muscle relaxant. It binds competitiv...

CAS 79416-27-6 5-Aminolevulinic acid methyl ester hydroChloride

5-Aminolevulinic acid methyl ester hydro
(CAS: 79416-27-6)

5-Aminolevulinic Acid Methyl Ester Hydrochlorideis the methyl ester of Aminolevulinic Acid. It shows much higher lipophilicity and highly efficient at inducing ...

ML281
(CAS: 1404437-62-2)

ML281, a quinoxalin derivative, has been found to be a STK33 inhibitor and could have probable effect against KRAS-dependent cancers. IC50: 14 nM.

CAS 114466-38-5 SERMORELIN ACETATE

SERMORELIN ACETATE
(CAS: 114466-38-5)

This polypeptide is a growth hormone-releasing hormone (GHRH) analogue which is made up of 29 amino acids. Sermorelin is recognized as the shortest fully functi...

Reference Reading


1.Prevention of preterm delivery with compounded 17a-hydroxyprogesterone caproate.
Reed-Kane D Pharmd Fiacp Faca Fc1, Kirschbaum K Phd. Int J Pharm Compd. 2006 May-Jun;10(3):165-71.
17a-hydroxyprogesterone caproate is a naturally occurring metabolite of progesterone that is produced in significant quantities during pregnancy. The demand for 17a-hydroxyprogesterone caproate, the lack of a commercially available manufactured form approved by the US Food And Drug Administration, and publication of the results of a large trial to determine the effectivenss of the drug in the prevention of preterm delivery have spawned an increased interest in compounded formulations of the drug. The demand also has necessitated a review of the available literature and of past clinical studies, and a look at present and planned studies. Owing to the importance of this drug in pregnancy and the need for safety, accuracy in potency, and sterility in an intramuscular injection (the most common route of administration), compounding pharmacies must be in compliance with the United States Pharmacopeia Chapter 797 standards should they wish to compound this formulation.
2.Low basal androstenedione levels plus augmented 17alpha-hydroxyprogesterone and low dehydroepiandrosterone sulfate responses to adrenocorticotropic hormone stimulation in patients with adrenal incidentaloma.
Ozgen AG1, Bayraktar F, Yilmaz C. Endocr Pract. 2001 Nov-Dec;7(6):448-53.
OBJECTIVE: To investigate the androstenedione, 17a-hydroxyprogesterone (17-OHP), and dehydroepiandrosterone sulfate (DHEAS) basal levels and responses to adrenocorticotropic hormone (ACTH) in patients with adrenal incidentalomas in order to determine which enzyme defects are present.
3.Congenital adrenal hyperplasia due to 21-hydroxylase deficiency - management in adults.
Ambroziak U, Bednarczuk T, Ginalska-Malinowska M, Małunowicz EM, Grzechocińska B, Kamiński P, Bablok L, Przedlacki J, Bar-Andziak E. Endokrynol Pol. 2010 Jan-Feb;61(1):142-55.
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive hereditary diseases. The impairment of cortisol synthesis leads to excessive stimulation of the adrenal glands by adrenocorticotropic hormone (ACTH), adrenal hyperplasia, and excessive androgen synthesis. The syndrome is characterised by a considerable correlation between the genotype and the phenotype with the type of CYP21A2 gene mutation affecting the severity of 21-hydroxylase deficiency. The clinical manifestations of CAH in adults result from adrenocortical and adrenomedullary insufficiency, hyperandrogenism, and the adverse effects of glucocorticosteroids used for the treatment of the condition. Non-classic CAH may sometimes be asymptomatic. In patients with classic CAH obesity, hyperinsulinaemia, insulin resistance, and hyperleptinaemia are more often seen than in the general population. These abnormalities promote the development of metabolic syndrome and its sequelae, including endothelial dysfunction, and cardiovascular disease.
4.In vitro-metabolism of 3H-progesterone in human testicular tissue: IV Before and after long-term gonadotrophin treatment; including one 47, XYY-male.
Berg AA, Kjessler B. Acta Endocrinol Suppl (Copenh). 1976;207:49-59.
Certain defects in the intratesticular androgen biogenetic system may lead to a significant impairment of gonadal function in total in the human male. In the present investigation, four males with impaired reproductive performance were analysed before and after long term treatment with gonadotrophic hormones with regard to their in vitro metabolism of 3H-progesterone in testicular incubates; one of whom representing the first instance of an XYY-male studied in some detail with regard to intratesticular steroidogenesis. A steroid metabolisc pattern of an "immature" type, i.e., possibly indicating a relative understimulation of the gonads by gonadotrophic hormones, in vivo, was found in one of the four patients, i.e., the XYY-male, inspite of normal levels of gonadotrophic hormones in the peripheral circulation. Gametic output was found to increase significantly during the course of gonadotrophin substitution therapy, and the individual steroid metabolic pattern also changed drastically towards a more mature type subsequent to therapy.